<DOC>
	<DOCNO>NCT02866721</DOCNO>
	<brief_summary>This study do test safe give stem cell adult patient Cystic Fibrosis ( CF ) . The kind stem cell study call allogeneic human mesenchymal stem cell MSCs . MSCs cell body grow different type cell respond various environmental situation . Allogeneic mean cell come another person ( donor ) . This study look whether safe give stem cell adult CF infusion tolerate . In future , study may do see stem cell new therapeutic treatment CF . Stem cell , like medical product intend treat , cure prevent disease , generally require approval U.S. Food Drug Administration ( FDA ) market . The FDA approve stem cell-based product usual medical care , specific blood form stem cell certain indication .</brief_summary>
	<brief_title>Safety Tolerability Study Allogeneic Mesenchymal Stem Cell Infusion Adults With Cystic Fibrosis</brief_title>
	<detailed_description>This prospective , single-center , dose-escalation , open-label interventional study evaluate safety tolerability allogeneic hMSCs 15 clinically stable subject CF age ≥ 18 year . After two six week screen period , subject Baseline visit ( Days 1-2 ) undergo single intravenous infusion 5 x 10EE6 allogeneic hMSCs/kg body weight . Infusions perform Dahms Clinical Research Unit ( DCRU ) University Hospitals Cleveland Medical Center . Subjects monitor infusion relate toxicity 24 hour infusion . Subsequent study visit occur Days 7 , 14 , 28 , Months 3 6 telephone call occur Days 4 ( 5 ) , 21 , 56 Month 12 . Subject safety tolerability single dose hMSCs evaluate study visit review subject diary , interval history , pulmonary exacerbation , physical examination , spirometry , analysis safety laboratory . Special attention place upon detect pulmonary exacerbation anti-inflammatory therapy theoretically could suppress immune system point lead increase infectious complication , although MSC therapeutic propose antimicrobial . In addition evaluate safety , study also explore efficacy end-points future clinical trial MSCs CF include inflammatory biomarkers blood sputum . Serum marker ( calprotectin , MPO , GM-CSF , IL-1β , IL-6 , IL8 , IL-17 , TNF-a ) sputum marker ( white cell count differential , IL-1β , IL-6 , IL-8 , IL-10 , IL-17 , GM-CSF , MIP- 3a , TNF-a , active protease include neutrophil elastase , a1-anti-trypsin , MMP-9 ) determine Baseline Days 7 28 with-in subject comparison . All subject sample archive future project . Finally , diagnostic bone marrow exam perform subject CF consent undergo optional procedure . Bone marrow sample bank used future translational study .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>CF Subject 1 . Male female 18 40 year age 2 . Confirmed diagnosis CF evidence 1 clinical feature consistent CF phenotype 1 follow criterion : 1 . Sweat chloride equal great 60 mEq/L quantitative pilocarpine iontophoresis test ( QPIT ) 2 . 2 wellcharacterized , disease cause mutation CFTR gene 3 . Clinically stable significant change health status within 2 week prior screen . 4 . FEV1 ≥ 50 % &amp; ≤ 100 % predict age base global lung function initiative equation screen visit 5 . Weight ≥ 40 kg screen visit 6 . Able perform repeatable , consistent effort pulmonary function test 7 . Written inform consent obtain subject . CF Subject 1 . Use investigational agent within 4week period prior Visit 1 ( Day 42 10 ) 2 . Chronic daily ( &gt; 10 mg ) alternate daily ( &gt; 20 mg alternate day ) use systemic corticosteroid within 4 week prior Visit 1 ( Day 42 10 ) initiation dosage systemic corticosteroid within 72 hour prior Visit 2 ( Day 1 ) . 3 . Use hydroxychloroquine immunosuppressant . 4 . Initiation new antibiotic ( oral , IV , and/or inhale ) part subject 's maintenance regimen treatment acute respiratory symptom within 2 week prior screen Visit 2 ( Day 1 ) 5 . Initiation new chronic therapy ( e.g. , Pulmozyme® , hypertonic saline , Kalydeco® , Orkambi® , highdose ibuprofen azithromycin , TOBI® , Cayston® , nebulized colistiin , bronchodilator , inhaled corticosteroid , etc . ) within 4 week prior screen 6 . Active treatment nontuberculous Mycobacteria 7 . History sputum culture positive Burkholderia cepacia complex organism previous 12 month . 8 . Current tobacco smoker 9 . Oxygen saturation &lt; 92 % room air Visit 1 ( Day 42 10 ) 10 . History pulmonary hypertension 11 . SGOT ( ALT ) SGPT ( AST ) &gt; 2.5 time upper limit normal screening , document biliary cirrhosis , portal hypertension 12 . Total bilirubin concentration &gt; 1.2 mg/dL screen 13 . Creatinine &gt; 1.8 mg/dL screen 14 . Pregnant , breastfeeding , unwilling practice birth control Visit 2 ( Day 1 ) Telephone Call 3 ( Day 56 ) ( acceptable form contraception : abstinence , hormonal birth control , intrauterine device , barrier method plus spermicidal agent ) , unless surgically sterilize postmenopausal 15 . Screening hematology white blood cell count &lt; 4.5 x 109 cells/L , hematocrit &lt; 30 % , platelet &lt; 150 x 109 platelets/L 16 . History invasive cancer require systemic therapy 17 . History organ transplantation 18 . Currently list lung transplantation potential list lung transplantation succeed 12 calendar month screen 19 . Subject unlikely complete study determine Investigator Inclusion Criteria Healthy Volunteer Donors : 1 . Male/female age ≥ 18 year ≤ 40 year 2 . Able understand sign ICF ( legally authorize representative permit ) Inclusion Criteria CF Donors : 1 . CF subject enrol main study consent optional procedure Exclusion Criteria Healthy Volunteer Donors CF Donors : 1 . Fever current illness day cell collection 2 . Evidence communicable disease 3 . Any significant change health status within 2 week prior cell collection PI/SubInvestigator deem relevant exclude participation 4 . Subject report history organ transplantation 5 . Subject report history HIV , hepatitis B C , syphilis 6 . For HV donor , subjectreported known history diagnose cystic fibrosis ( CF ) CF carrier ( one copy CF gene mutation ) 7 . Positive screening blood test result infectious disease . 8 . For HV donor , positive test result CMV CF gene mutation . 9 . Pregnant , plan pregnancy , breastfeed screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Human Mesenchymal Stem Cells</keyword>
</DOC>